Drug interactions with new and investigational antiretrovirals.

Article Details

Citation

Brown KC, Paul S, Kashuba AD

Drug interactions with new and investigational antiretrovirals.

Clin Pharmacokinet. 2009;48(4):211-41.

PubMed ID
19492868 [ View in PubMed
]
Abstract

More than 20 individual and fixed-dose combinations of antiretrovirals are approved for the treatment of human immunodeficiency virus (HIV) infection. However, owing to the ongoing limitations of drug resistance and adverse effects, new treatment options are still required. A number of promising new agents in existing or new drug classes are in development or have recently been approved by the US FDA. Since these agents will be used in combination with other new and existing antiretrovirals, understanding the potential for drug interactions between these compounds is critical to their appropriate use. This article summarizes the drug interaction potential of new and investigational protease inhibitors (darunavir), non-nucleoside reverse transcriptase inhibitors (etravirine and rilpivirine), chemokine receptor antagonists (maraviroc, vicriviroc and INCB 9471), integrase inhibitors (raltegravir and elvitegravir) and maturation inhibitors (bevirimat).

DrugBank Data that Cites this Article

Drug Enzymes
DrugEnzymeKindOrganismPharmacological ActionActions
DarunavirCytochrome P450 3A4ProteinHumans
Unknown
Substrate
Inhibitor
Details
Drug Interactions
DrugsInteraction
Abemaciclib
Darunavir
The serum concentration of Abemaciclib can be increased when it is combined with Darunavir.
Acalabrutinib
Darunavir
The serum concentration of Acalabrutinib can be increased when it is combined with Darunavir.
Acenocoumarol
Darunavir
The serum concentration of Acenocoumarol can be increased when it is combined with Darunavir.
Alectinib
Darunavir
The serum concentration of Alectinib can be increased when it is combined with Darunavir.
Alpelisib
Darunavir
The serum concentration of Alpelisib can be increased when it is combined with Darunavir.